Last 12 months
Inside the activity.
3 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 3 |
| Dec 2025 | 2 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 4 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 27, 2023 Filed Jun 29, 2023 20:22 UTC |
Riva AlessandroDirector
|
GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014172 · form4.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:21 UTC |
JIMENEZ JOSEPHDirector
|
GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014171 · form4.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:20 UTC |
BUTITTA CYNTHIA MDirector
|
GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014169 · form4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:20 UTC |
Blackwell KimberlyDirector
|
GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014168 · form4.xml · derivative · entry 1 Blackwell Kimberly · CIK 0001816465 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:19 UTC |
Quimi DaphneDirector
|
GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014166 · form4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:18 UTC |
Walbert Timothy PDirector
|
GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014165 · form4.xml · derivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:33 UTC |
Carr DouglasSVP Finance & Operations
|
GrantCommon Stock | 120,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011404 · form4.xml · nonDerivative · entry 1 Carr Douglas · CIK 0001867173 · SVP Finance & Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,391 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs shall vest 50% on November 1, 2023, with the remaining 50% vesting upon the earlier of: (i) November 1, 2024; and (ii) satisfaction of certain performance criteria, in each case subject to the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:32 UTC |
Diem Michael CraigChief Financial Officer
|
GrantCommon Stock | 151,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011401 · form4.xml · nonDerivative · entry 1 Diem Michael Craig · CIK 0001497624 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,296 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs shall vest 50% on November 1, 2023, with the remaining 50% vesting upon the earlier of: (i) November 1, 2024; and (ii) satisfaction of certain performance criteria, in each case subject to the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 23:56 UTC |
Levitsky HyamPresident of R&D
|
GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001062993-23-009200 · form4.xml · derivative · entry 1 Levitsky Hyam · CIK 0001375792 · President of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-04-12 F1 · derivative.exercise_date: The option vests 25% on April 12, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 21:29 UTC |
Russotti GregoryChief Technology Officer
|
GrantStock Option (right to buy) · Derivative | 318,750 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001062993-23-009152 · form4.xml · derivative · entry 1 Russotti Gregory · CIK 0001867305 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,750 Underlying: Common Stock · 318,750 shares Expires 2033-04-11 F1 · derivative.exercise_date: The option vests 25% on April 11, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:27 UTC |
Borges LuisChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,452 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001062993-23-008770 · form4.xml · derivative · entry 2 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,452 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: As of the date hereof, these stock options are vested and currently exercisable. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:27 UTC |
Borges LuisChief Scientific Officer
|
Exercise / conversionCommon Stock | 7,452 | $1.03 | $7,675.56 |
DisclosureSEC source: 0001062993-23-008770 · form4.xml · nonDerivative · entry 1 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 220,930 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · derivative · entry 9 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,452 Underlying: Common Stock · 220,930 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests 25% on April 1, 2020, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
SaleCommon Stock | 15,597 | $3.55 | $55,369.35 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · nonDerivative · entry 6 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 249,083 Read SEC document |
| March 23, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
Exercise / conversionCommon Stock | 220,930 | $1.03 | $227,557.90 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · nonDerivative · entry 5 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 65,698 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · derivative · entry 8 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,382 Underlying: Common Stock · 65,698 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests 25% on April 1, 2020, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
SaleCommon Stock | 65,698 | $3.72 | $244,639.64 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · nonDerivative · entry 4 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,750 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.57 to $3.79, inclusive. Read SEC document |
| March 22, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
Exercise / conversionCommon Stock | 65,698 | $1.03 | $67,668.94 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · nonDerivative · entry 3 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,448 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 63,616 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · derivative · entry 7 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 294,080 Underlying: Common Stock · 63,616 shares Expires 2029-07-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests 25% on April 1, 2020, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
SaleCommon Stock | 63,616 | $3.77 | $239,870.49 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · nonDerivative · entry 2 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,750 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.75 to $3.935, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| March 21, 2023 Filed Mar 23, 2023 23:31 UTC |
Borges LuisChief Scientific Officer
|
Exercise / conversionCommon Stock | 63,616 | $1.03 | $65,524.48 |
DisclosureSEC source: 0001062993-23-007574 · form4.xml · nonDerivative · entry 1 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:52 UTC |
Flores OsvaldoChief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 637,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002312 · form4.xml · derivative · entry 2 Flores Osvaldo · CIK 0001867301 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,500 Underlying: Common Stock · 637,500 shares Expires 2033-02-02 F1 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:52 UTC |
Flores OsvaldoChief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 637,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002312 · form4.xml · derivative · entry 1 Flores Osvaldo · CIK 0001867301 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,500 Underlying: Common Stock · 637,500 shares Expires 2033-02-02 F1 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:52 UTC |
Carr DouglasVP Finance & Operations
|
GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002311 · form4.xml · derivative · entry 4 Carr Douglas · CIK 0001867173 · VP Finance & Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:52 UTC |
Carr DouglasVP Finance & Operations
|
GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002311 · form4.xml · derivative · entry 3 Carr Douglas · CIK 0001867173 · VP Finance & Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:52 UTC |
Carr DouglasVP Finance & Operations
|
GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002311 · form4.xml · nonDerivative · entry 2 Carr Douglas · CIK 0001867173 · VP Finance & Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,545 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:52 UTC |
Carr DouglasVP Finance & Operations
|
GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002311 · form4.xml · nonDerivative · entry 1 Carr Douglas · CIK 0001867173 · VP Finance & Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,045 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:51 UTC |
Russotti GregoryChief Technology Officer
|
GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002310 · form4.xml · derivative · entry 2 Russotti Gregory · CIK 0001867305 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:51 UTC |
Russotti GregoryChief Technology Officer
|
GrantStock Option (right to buy) · Derivative | 175,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002310 · form4.xml · derivative · entry 1 Russotti Gregory · CIK 0001867305 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-02-02 F1 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:50 UTC |
Borges LuisChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002309 · form4.xml · derivative · entry 4 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:50 UTC |
Borges LuisChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002309 · form4.xml · derivative · entry 3 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:50 UTC |
Borges LuisChief Scientific Officer
|
GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002309 · form4.xml · nonDerivative · entry 2 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:50 UTC |
Borges LuisChief Scientific Officer
|
GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002309 · form4.xml · nonDerivative · entry 1 Borges Luis · CIK 0001684015 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,875 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC |
Farid AdrienneChief Operations Officer
|
GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002308 · form4.xml · derivative · entry 4 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC |
Farid AdrienneChief Operations Officer
|
GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002308 · form4.xml · derivative · entry 3 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC |
Farid AdrienneChief Operations Officer
|
GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002308 · form4.xml · nonDerivative · entry 2 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,968 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC |
Farid AdrienneChief Operations Officer
|
GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002308 · form4.xml · nonDerivative · entry 1 Farid Adrienne · CIK 0001867310 · Chief Operations Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,093 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC |
Diem Michael CraigChief Business Officer
|
GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002307 · form4.xml · derivative · entry 4 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC |
Diem Michael CraigChief Business Officer
|
GrantStock Option (right to buy) · Derivative | 131,250 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001062993-23-002307 · form4.xml · derivative · entry 3 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2033-02-02 F2 · derivative.exercise_date: The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC |
Diem Michael CraigChief Business Officer
|
GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002307 · form4.xml · nonDerivative · entry 2 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,238 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 23:49 UTC |
Diem Michael CraigChief Business Officer
|
GrantCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-002307 · form4.xml · nonDerivative · entry 1 Diem Michael Craig · CIK 0001497624 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,363 F1 · security: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. Read SEC document |
| October 01, 2022 Filed Oct 3, 2022 20:08 UTC |
Quimi DaphneDirector
|
GrantStock Option (right to buy) · Derivative | 39,744 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001062993-22-020144 · form4.xml · derivative · entry 1 Quimi Daphne · CIK 0001543031 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,744 Underlying: Common Stock · 39,744 shares Expires 2032-10-01 F1 · derivative.exercise_date: Century Therapeutics, Inc. (the "Company") issued Ms. Quimi stock options (the "Options") in connection with her appointment as a director. The Options vest in equal monthly installments over 36 months subject to Ms. Quimi's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan. Read SEC document |
| October 01, 2022 Filed Oct 3, 2022 20:07 UTC |
Walbert Timothy PDirector
|
GrantStock Option (right to buy) · Derivative | 39,744 | $0.00 Strike: $9.89 | $0.00 |
DisclosureSEC source: 0001062993-22-020143 · form4.xml · derivative · entry 1 Walbert Timothy P · CIK 0001349376 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,744 Underlying: Common Stock · 39,744 shares Expires 2032-10-01 F1 · derivative.exercise_date: Century Therapeutics, Inc. (the "Company") issued Mr. Walbert stock options (the "Options") in connection with his appointment as a director. The Options vest in equal monthly installments over 36 months subject to Mr. Walbert's continued service to the Company and are issued pursuant to the Company's 2021 Equity Incentive Plan. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:55 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
|
OtherCommon Stock | 364,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-028388 · doc4.xml · nonDerivative · entry 2 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,452,014 F4 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant VI to its limited partners pursuant to a Rule 10b5-1 trading plan. F3 · ownership.direct: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein. Read SEC document |
| August 09, 2022 Filed Aug 11, 2022 20:55 UTC |
Versant Venture Capital VI, L.P.10% owner
Versant Ventures VI GP, L.P.10% owner
Versant Ventures VI GP-GP, LLC10% owner
Versant Vantage II, L.P.10% owner
Versant Vantage II GP, L.P.10% owner
Versant Vantage II GP-GP, LLC10% owner
|
SaleCommon Stock | 550,000 | $13.03 | $7,166,610.00 |
DisclosureSEC source: 0000899243-22-028388 · doc4.xml · nonDerivative · entry 1 Versant Venture Capital VI, L.P. · CIK 0001687880 · 10% owner Versant Ventures VI GP, L.P. · CIK 0001777654 · 10% owner Versant Ventures VI GP-GP, LLC · CIK 0001777652 · 10% owner Versant Vantage II, L.P. · CIK 0001832235 · 10% owner Versant Vantage II GP, L.P. · CIK 0001839790 · 10% owner Versant Vantage II GP-GP, LLC · CIK 0001839789 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,816,814 F1 · kind: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital VI, L.P. ("Versant VI"). F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $13.03 to $13.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F3 · ownership.direct: The reportable securities are owned directly by Versant VI. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Each of Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:23 UTC |
BUTITTA CYNTHIA MDirector
|
GrantStock Option (right to buy) · Derivative | 19,872 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001062993-22-014659 · form4.xml · derivative · entry 1 BUTITTA CYNTHIA M · CIK 0001222082 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:21 UTC |
Carlo RizzutoDirector
|
GrantStock Option (right to buy) · Derivative | 19,872 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001062993-22-014653 · form4.xml · derivative · entry 1 Carlo Rizzuto · CIK 0001817033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:23 UTC |
Riva AlessandroDirector
|
GrantStock Option (right to buy) · Derivative | 19,872 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001062993-22-014657 · form4.xml · derivative · entry 1 Riva Alessandro · CIK 0001867172 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:22 UTC |
JIMENEZ JOSEPHDirector
|
GrantStock Option (right to buy) · Derivative | 19,872 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001062993-22-014654 · form4.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:23 UTC |
Blackwell KimberlyDirector
|
GrantStock Option (right to buy) · Derivative | 19,872 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001062993-22-014656 · form4.xml · derivative · entry 1 Blackwell Kimberly · CIK 0001816465 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.